Extreme Investor Network is excited to share the latest news from Eli Lilly regarding their weight loss drug Zepbound. The pharmaceutical giant recently applied for U.S. approval of Zepbound for the treatment of obstructive sleep apnea (OSA), the most common sleep-related breathing disorder. If the Food and Drug Administration approves the drug, Eli Lilly plans to launch Zepbound at the beginning of 2025.
Additional data from two late-stage trials presented at the American Diabetes Association’s 84th Scientific Sessions showed that Zepbound helped resolve OSA in almost half of patients. This new data has exceeded expectations and could lead to broader insurance coverage for the drug, which is currently not covered by many insurance plans.
According to Eli Lilly, an estimated 80 million people in the U.S. suffer from OSA, with 20 million of them having moderate-to-severe forms of the disease. However, 85% of OSA cases go undiagnosed, highlighting the need for effective treatments like Zepbound.
The results from the trials showed that Zepbound was more effective than a placebo at reducing the severity of OSA in patients with obesity. Patients who took the highest dose of Zepbound achieved disease resolution in significant numbers compared to those who took a placebo.
This groundbreaking data has the potential to significantly impact patients’ lives by reducing the need for cumbersome PAP machines and improving overall quality of sleep. Eli Lilly’s fast track designation from the FDA for Zepbound further emphasizes the drug’s potential to address a serious medical need.
Stay tuned to Extreme Investor Network for more updates on Eli Lilly’s innovative treatments and groundbreaking advancements in the world of pharmaceuticals. Experience the power of informed investing with us.